John A. Roush Sells 939 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Director John A. Roush sold 939 shares of LeMaitre Vascular stock in a transaction on Friday, August 8th. The stock was sold at an average price of $93.49, for a total transaction of $87,787.11. Following the sale, the director owned 2,916 shares in the company, valued at $272,616.84. This represents a 24.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

LeMaitre Vascular Stock Performance

LMAT opened at $95.91 on Friday. The business’s 50-day moving average price is $84.56 and its two-hundred day moving average price is $86.53. LeMaitre Vascular, Inc. has a 1 year low of $71.42 and a 1 year high of $109.58. The company has a market capitalization of $2.17 billion, a price-to-earnings ratio of 46.56, a P/E/G ratio of 2.46 and a beta of 0.79. The company has a debt-to-equity ratio of 0.46, a current ratio of 13.96 and a quick ratio of 11.74.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.03. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%. The firm had revenue of $63.15 million for the quarter, compared to the consensus estimate of $62.48 million. During the same quarter last year, the business posted $0.52 EPS. The company’s revenue for the quarter was up 15.0% on a year-over-year basis. Equities analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 4th. Investors of record on Thursday, August 21st will be given a $0.20 dividend. The ex-dividend date of this dividend is Thursday, August 21st. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.8%. LeMaitre Vascular’s payout ratio is currently 38.83%.

Hedge Funds Weigh In On LeMaitre Vascular

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC grew its holdings in LeMaitre Vascular by 398.9% during the second quarter. Tower Research Capital LLC TRC now owns 1,736 shares of the medical instruments supplier’s stock worth $144,000 after purchasing an additional 1,388 shares during the period. Captrust Financial Advisors grew its holdings in LeMaitre Vascular by 149.4% during the second quarter. Captrust Financial Advisors now owns 9,446 shares of the medical instruments supplier’s stock worth $784,000 after purchasing an additional 5,659 shares during the period. Scott Marsh Financial LLC bought a new position in LeMaitre Vascular during the second quarter worth about $581,000. Lazard Asset Management LLC grew its holdings in LeMaitre Vascular by 14.7% during the second quarter. Lazard Asset Management LLC now owns 45,762 shares of the medical instruments supplier’s stock worth $3,800,000 after purchasing an additional 5,849 shares during the period. Finally, Engineers Gate Manager LP grew its holdings in LeMaitre Vascular by 204.9% during the second quarter. Engineers Gate Manager LP now owns 8,468 shares of the medical instruments supplier’s stock worth $703,000 after purchasing an additional 5,691 shares during the period. Institutional investors own 84.64% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Barrington Research upgraded shares of LeMaitre Vascular from a “market perform” rating to an “outperform” rating and set a $95.00 target price on the stock in a research note on Wednesday, August 6th. Cantor Fitzgerald boosted their target price on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $98.00.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.